PC190723

Antibacterial; an inhibitor of FtsZ with potent and selective anti-staphylococcal activity including methicillin- and multi-drug-resistant Staphylococcus aureus; structure in first source

Networked: 3 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Kaul, Malvika: 1 article (12/2013)
2.	Lavoie, Edmond J: 1 article (12/2013)
3.	Mark, Lilly: 1 article (12/2013)
4.	Parhi, Ajit K: 1 article (12/2013)
5.	Pilch, Daniel S: 1 article (12/2013)
6.	Zhang, Yongzheng: 1 article (12/2013)
7.	Baryshnikova, Anastasia: 1 article (03/2012)
8.	Benton-Perdomo, Liliana: 1 article (03/2012)
9.	Caron, Alexandre: 1 article (03/2012)
10.	Claveau, David: 1 article (03/2012)

Related Diseases

1.

Infections 09/19/2008 - "PC190723 was efficacious in an in vivo model of infection, curing mice infected with a lethal dose of S. " 12/01/2013 - "The benzamide PC190723 was among the first FtsZ-targeting compounds to exhibit in vivo efficacy in a murine infection model system. " 03/21/2012 - "We demonstrate that the FtsZ-specific inhibitor PC190723 acts synergistically with β-lactam antibiotics in vitro and in vivo and that this combination is efficacious in a murine model of MRSA infection. "

Related Drugs and Biologics

1.	Lactams
2.	Anti-Bacterial Agents (Antibiotics)
3.	benzamide